Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Saved in:
| Title: | Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. |
|---|---|
| Authors: | Weinstock-Guttman B; University at Buffalo, Buffalo, NY, USA., Bermel R; Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA., Cutter G; University of Alabama at Birmingham, Birmingham, AL, USA., Freedman MS; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Leist TP; Thomas Jefferson University, Philadelphia, PA, USA., Ma X; Genentech, Inc., South San Francisco, CA, USA., Kile D; Genentech, Inc., South San Francisco, CA, USA., Musch B; Genentech, Inc., South San Francisco, CA, USA., Reder AT; University of Chicago, Chicago, IL, USA., Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Apr; Vol. 28 (5), pp. 790-800. Date of Electronic Publication: 2021 Aug 12. |
| Publication Type: | Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34382875 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Weinstock-Guttman+B%22">Weinstock-Guttman B</searchLink>; University at Buffalo, Buffalo, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bermel+R%22">Bermel R</searchLink>; Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Cutter+G%22">Cutter G</searchLink>; University of Alabama at Birmingham, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Freedman+MS%22">Freedman MS</searchLink>; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Leist+TP%22">Leist TP</searchLink>; Thomas Jefferson University, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Ma+X%22">Ma X</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kile+D%22">Kile D</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Musch+B%22">Musch B</searchLink>; Genentech, Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Reder+AT%22">Reder AT</searchLink>; University of Chicago, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Wolinsky+JS%22">Wolinsky JS</searchLink>; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229509185%22">Multiple sclerosis (Houndmills, Basingstoke, England)</searchLink> [Mult Scler] 2022 Apr; Vol. 28 (5), pp. 790-800. <i>Date of Electronic Publication: </i>2021 Aug 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9509185 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-0970 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213524585%22">13524585 </searchLink><i>NLM ISO Abbreviation: </i>Mult Scler <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34382875 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1177/13524585211035740 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 790 Titles: – TitleFull: Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Weinstock-Guttman B – PersonEntity: Name: NameFull: Bermel R – PersonEntity: Name: NameFull: Cutter G – PersonEntity: Name: NameFull: Freedman MS – PersonEntity: Name: NameFull: Leist TP – PersonEntity: Name: NameFull: Ma X – PersonEntity: Name: NameFull: Kile D – PersonEntity: Name: NameFull: Musch B – PersonEntity: Name: NameFull: Reder AT – PersonEntity: Name: NameFull: Wolinsky JS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2022 Apr Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1477-0970 Numbering: – Type: volume Value: 28 – Type: issue Value: 5 Titles: – TitleFull: Multiple sclerosis (Houndmills, Basingstoke, England) Type: main |
| ResultId | 1 |
